Science Corner with David Friedberg: GLP-1 Study Shows Encouraging Results

David Friedberg highlighted a VA study comparing roughly 215,000 GLP-1 users with 1.2 million untreated diabetics and about 600,000 patients on other diabetes drugs. He said the GLP-1 group showed lower risks across several conditions, including roughly 30% lower cardiac-arrest risk, while the main increases were gastrointestinal and related side effects.

Friedberg’s main takeaway was that GLP-1 drugs may do more than cause weight loss. He pointed to emerging evidence of direct biological effects—such as changes in inflammation, gene expression and cellular repair—and said researchers are beginning to see benefits in non-obese users that cannot be explained simply by losing fat.

Despite the promising data, Friedberg said he would not put his children on GLP-1s and would only consider them for himself or his wife. His hesitation centers on muscle and bone-density loss, which is why he wants to increase protein intake and establish a stronger weightlifting routine before deciding whether to take one.

Friedberg is deliberately trying exercise and higher protein first so he can separate their effects from any later GLP-1 treatment. He said he wants to build more muscle before adding the drug, rather than change both variables at once and lose the ability to tell what actually improved his health.

Chamath Palihapitiya said the modern health-optimization industry became so complicated that even having doctors in Los Angeles and San Francisco made his care worse. He spent heavily comparing competing protocols and concluded he would rather follow one simple, coherent plan than constantly reconcile advice from doctors, podcasters and supplement advocates.

Chamath’s intense focus on preventive health is personal: he said his father and his best friend both died from poor health. That history helps explain why he repeatedly experiments with monitoring, supplements and protocols even while acknowledging that the search for optimization can itself become obsessive.

The group saw simplicity—not just efficacy—as a major reason GLP-1s could keep expanding. They contrasted complicated lifestyle and supplement regimens with a drug that can reduce weight and potentially improve other health markers with little daily decision-making, especially as oral versions approach the market.